• Ferroptosis-Driven Macrophage Reprogramming Boosts Immunothe

  2026-07-08

  This study reveals that ferroptosis in tumor cells enhances anti-tumor immunity by reprogramming macrophage antigen presentation. By elucidating a mechanistic link between ferroptotic stress and MHC-II upregulation, the findings suggest new avenues to synergize ferroptosis induction with immune checkpoint blockade in cancer therapy.

• Viral Degradation of RIPK3 Regulates Necroptosis and Inflamm

  2026-07-07

  Liu et al. identified a novel class of orthopoxvirus proteins that induce proteasomal degradation of RIPK3, thereby suppressing necroptosis and modulating virus-induced inflammation. This discovery elucidates a key viral immune evasion mechanism and highlights potential targets for manipulating cell death pathways in infection and inflammation research.

• Toremifene in Breast Cancer: 20-Year Review and Clinical Ins

  2026-07-07

  This review synthesizes two decades of clinical evidence on toremifene, a selective estrogen receptor modulator, highlighting its efficacy, safety, and pharmacogenetic considerations in breast cancer therapy. The paper contextualizes toremifene’s role alongside aromatase inhibitors and informs biomarker-driven, individualized treatment strategies.

• Aclacinomycin A as a Precision Tool for Nucleolar DNA Damage

  2026-07-06

  Discover how Aclacinomycin A serves as a powerful DNA damage inducer and apoptosis modulator in advanced nucleolar stress research. This article uniquely explores its mechanistic interplay with PML-nucleolar dynamics, offering insights beyond conventional DNA damage workflows.

• Telmisartan in Cardiac Hypertrophy: Pathway Dissection & Exp

  2026-07-06

  Explore Telmisartan as a potent angiotensin II receptor antagonist for cardiovascular and hypertension research. This in-depth analysis reveals new mechanistic insights, rigorous protocol strategies, and expert evaluations of its utility in dissecting cardiac hypertrophy pathways.

• Anlotinib Hydrochloride: Optimizing Multi-Target TKI Angioge

  2026-07-05

  Anlotinib hydrochloride, a multi-target tyrosine kinase inhibitor, redefines experimental angiogenesis workflows with superior selectivity and inhibition potency. Discover how to leverage its anti-angiogenic effects in functional assays, troubleshoot common experimental pitfalls, and translate cutting-edge findings into robust, reproducible cancer research.

• DMXAA (Vadimezan): Protocol Innovation in Tumor Vascular Dis

  2026-07-04

  DMXAA (Vadimezan) uniquely enables rapid, selective tumor vasculature disruption and apoptosis in preclinical cancer models. This article delivers advanced protocols, troubleshooting strategies, and new insights from endothelial signaling research—empowering cancer biology workflows with actionable precision.

• Angiotensin III: Applied Workflows for Cardiovascular Resear

  2026-07-03

  Angiotensin III (human, mouse) empowers advanced cardiovascular and neuroendocrine research with quantifiable pressor and aldosterone effects, superior receptor selectivity, and robust cross-domain insight into viral pathogenesis. This guide delivers protocol-ready strategies, troubleshooting tips, and translational guidance for maximizing experimental success with APExBIO’s validated peptide.

• Trifluoperazine 2HCl: Dopamine D2 Inhibition & Immune Modula

  2026-07-03

  Trifluoperazine 2HCl is a potent dopamine D2 receptor inhibitor with nanomolar affinity, enabling precise modulation of dopaminergic signaling. Validated in both neuropharmacology and immunological models, it induces autophagy and ROS in macrophages, expanding its use beyond classic neuroscience research. Its robust solubility profile and research-grade purity from APExBIO make it a versatile tool for multidomain biomedical assays.

• Efficient iPSC-to-Retinal Ganglion Cell Differentiation via

  2026-07-02

  The reference study establishes a chemically defined, highly reproducible protocol for differentiating human induced pluripotent stem cells (iPSCs) into retinal ganglion cells (RGCs) with over 80% purity. By inhibiting SMAD and Wnt pathways, the protocol addresses previous challenges of variability and low yield, advancing stem cell-based research for glaucoma and neurodegeneration.

• Cy7 NHS Ester: Technical Reference for Near-Infrared Labelin

  2026-07-02

  Cy7 NHS ester enables reliable, water-soluble labeling of amino groups in proteins and peptides for near-infrared imaging, reducing quenching and minimizing protein denaturation risk. It is best suited for applications requiring high-sensitivity fluorescent tracking in live or delicate systems. This reagent should not be used where long-term dye solution stability or non-amino group labeling is required.

• ICG001 (SKU A8217): Reliable Wnt/β-Catenin Pathway Inhibitio

  2026-07-01

  This article provides laboratory-driven guidance on using ICG001 (SKU A8217) as a selective Wnt/β-catenin pathway inhibitor. Addressing real-world assay challenges, we examine protocol optimization, data interpretation, and product reliability, supporting every claim with referenced evidence. APExBIO's ICG001 is positioned as a reproducible, data-backed solution for cancer, fibrosis, and signaling research.

• Actinomycin D in Chemoresistance: mRNA Stability and Ferropt

  2026-07-01

  Explore how Actinomycin D advances cancer research by dissecting mRNA stability and ferroptosis resistance. This in-depth analysis reveals novel insights into transcriptional stress, apoptosis induction, and emerging assay strategies.

• β-Amanitin in Transcription Studies: Workflows & Innovations

  2026-06-30

  β-Amanitin empowers researchers to dissect eukaryotic transcription with precision, serving as the gold standard for RNA polymerase II inhibition. Leveraging APExBIO’s high-purity formulation, scientists can optimize mRNA synthesis assays and drive advances in molecular toxicology and rapid toxin detection.

• Abiraterone Acetate: Strategy and Science for 3D Prostate Ca

  2026-06-30

  This thought-leadership article explores the mechanistic, experimental, and strategic dimensions of Abiraterone acetate as a CYP17 inhibitor in translational prostate cancer research. Emphasizing the synergy between mechanistic insight and model innovation, it provides guidance for researchers leveraging patient-derived 3D spheroids, evaluates competitive inhibitor landscapes, and articulates how APExBIO’s Abiraterone acetate (SKU A8202) uniquely empowers reproducible, high-fidelity androgen pathway interrogation.

451 records 12/31 page Previous Next First page 上5页 1112131415 下5页 Last page